Compare DexCom, Inc. (DXCM) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ING Groep NV — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while ING Groep NV trades at $33.37 (market cap $93.76B). The key difference: ING Groep NV is far larger — about 2.9× DexCom, Inc.'s market cap, and ING Groep NV pays a 3.95% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ING Groep NV for 94 Days on average.
| DXCM | ING | |
|---|---|---|
Market Cap | $31.86B | $93.76B |
Volume | 3,607,070 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $92.34 | $37.27 |
52-Week Low | $54.84 | $23.66 |
Typical Hold Time | 62 Days | 94 Days |
Enterprise Value | $31.32B | $236.48B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
ING stock trades at $33.43, down 1.44% with a bearish technical outlook. The company shows strong fundamentals with consistent earnings beats, a 28.34% net margin, and positive analyst sentiment (64.71% buy ratings). Recent news highlights management's raised ROE target to 16% for 2027 and upgraded revenue guidance, though cash flow trends remain negative.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include persistent negative cash flows and regulatory scrutiny in Australia. The stock presents value with a reasonable P/E of 12.86, supported by dividend payments and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
